Sign in
Active, not recruitingNo phase

Comparison of TAVR With SAVR in Younger Low Surgical Risk Patients With Severe Aortic Stenosis

Key facts

Who runs it
Ole De Backer
Where
Denmark, Finland, Iceland, Norway, and Sweden9 sites in 5 countriesChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
376 people enrolled
Started
30 Jun 2016
Expected to end
Jun 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Transcatheter aortic valve replacement
  • Surgical aortic valve replacement
Record updated
9 April 2024

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age 75 years or younger
  • Severe calcific AS (Valve area <1cm2 (or <0.6 cm2/m2) AND one of the two following criteria: mean gradient >40mmHg or peak jet velocity >4.0m/s, OR in presence of low flow, low gradient with reduced or normal LVEF<50%, a dobutamine stress echo should verify true severe AS rather than pseudo-AS
  • Symptomatic with angina pectoris, dyspnea or exercise-induced syncope or near syncope OR asymptomatic with abnormal exercise test showing symptoms on exercise clearly related to AS or systolic LV dysfunction (LVEF <50%) not due to another cause
  • Anticipated usage of biological aortic valve prosthesis
  • Low risk for conventional surgery (STS Score <4%)
  • Suitable for both SAVR and transfemoral TAVR
  • Life expectancy >1 year after the intervention
  • Informed consent to participate in the study after adequate information about the study before randomization and intervention

Who cannot take part

  • Coronary artery disease, not suitable for both percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG)
  • Porcelain aorta, which prevents open-heart surgery
  • Need for open heart surgery other than SAVR with or without CABG
  • Myocardial infarction within last 30 days
  • Stroke or TIA within the last 30 days. NOTION-2, 01. February 2017, version 5 9
  • Ongoing severe infection requiring intravenous antibiotics
  • Unstable pre-procedural condition requiring intravenous inotropes or mechanical assist device (IABP, Impella) on the day of intervention
  • Kidney disease requiring dialysis or severely impaired lung function (FEV1 and/or diffusion capacity <40% of predicted)
  • Allergy to heparin, iodid contrast agent, warfarin, aspirin or clopidogrel
  • LVEF <25% without contractile reserve during dobutamine stress echocardiography
  • Coronary angiogram with a SYNTAX-score >22
  • Bicuspid valve with aorta ascendens diameter ≥45mm
  • Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm or tortuosity, which prevents transfemoral TAVR
  • Current endocarditis, intracardiac tumor, thrombus or vegetation

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

A randomized clinical trial investigating transcatheter (TAVR) versus surgical (SAVR) aortic valve replacement in patients 75 years of age or younger suffering from severe aortic valve stenosis.

Read full original descriptionShow less

Study hypothesis: The clinical outcome (death of any cause, stroke and rehospitalization (related to the procedure, valve or heart failure)) obtained within one year after TAVR is non-inferior to SAVR.

The 2 groups in the trial

  • Transcatheter aortic valve replacementTreatment being tested
  • Surgical aortic valve replacementExisting treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Nordic Aortic Valve Intervention Trial 2 - A Randomized Multicenter Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis
Publications
Record updated
9 April 2024